Microenvironmental Influences that Drive Progression from Benign Breast Disease to Invasive Breast Cancer
暂无分享,去创建一个
[1] H M Jensen,et al. On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.
[2] H M Jensen,et al. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. , 1975, Journal of the National Cancer Institute.
[3] W D Dupont,et al. Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.
[4] Jose Russo,et al. Human Breast Epithelial Cell Line, MCF-10 Isolation and Characterization of a Spontaneously Immortalized , 2006 .
[5] S J London,et al. A prospective study of benign breast disease and the risk of breast cancer. , 1992, JAMA.
[6] F. Miller,et al. Xenograft model of progressive human proliferative breast disease. , 1993, Journal of the National Cancer Institute.
[7] F. Miller,et al. The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. , 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[8] Anthony J. Guidi,et al. Microvessel density and distribution in ductal carcinoma in situ of the breast. , 1994, Journal of the National Cancer Institute.
[9] S. Kamel,et al. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer , 1996, Journal of cellular biochemistry. Supplement.
[10] S. Barsky,et al. The myoepithelial defense: a host defense against cancer. , 1997, Medical hypotheses.
[11] Z. Shao,et al. The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] P. O’Connell,et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.
[13] A. Gown,et al. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast , 1999, Virchows Archiv.
[14] U. Sauer,et al. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. , 1999, Anticancer research.
[15] F. Miller,et al. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. , 2000, Journal of the National Cancer Institute.
[16] P. Hein,et al. Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.
[17] S. Fuqua,et al. Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.
[18] Mina J Bissell,et al. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. , 2010, Journal of cell science.
[19] R. Salunga,et al. Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] L. Kiemeney,et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Hudis,et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations , 2003, Cancer.
[22] F. Miller,et al. Progression of Premalignant MCF10AT Generates Heterogeneous Malignant Variants with Characteristic Histologic Types and Immunohistochemical Markers , 2000, Breast Cancer Research and Treatment.
[23] Rameen Beroukhim,et al. Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.
[24] Fred R. Miller,et al. Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.
[25] R. Weinberg,et al. Reconstruction of functionally normal and malignant human breast tissues in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Heffelfinger,et al. Endometase/Matrilysin-2 in Human Breast Ductal Carcinoma in Situ and Its Inhibition by Tissue Inhibitors of Metalloproteinases-2 and -4 , 2004, Cancer Research.
[27] F. Miller. Xenograft Models of Premalignant Breast Disease , 2000, Journal of Mammary Gland Biology and Neoplasia.
[28] P. Gattuso,et al. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. , 2005, Journal of the American College of Surgeons.
[29] R. Mansel,et al. Benign breast disorders. , 2005, The New England journal of medicine.
[30] Tina Hernandez-Boussard,et al. Determination of Stromal Signatures in Breast Carcinoma , 2005, PLoS biology.
[31] D. Axelrod,et al. Evaluation of pathways for progression of heterogeneous breast tumors. , 2005, Journal of theoretical biology.
[32] D. Proia,et al. Stroma: Tumor Agonist or Antagonist , 2005, Cell cycle.
[33] Kornelia Polyak,et al. Do Myoepithelial Cells Hold the Key for Breast Tumor Progression? , 2005, Journal of Mammary Gland Biology and Neoplasia.
[34] Jun Yao,et al. Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.
[35] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[36] Mina J Bissell,et al. Myoepithelial cells: good fences make good neighbors , 2005, Breast Cancer Research.
[37] Charlotte Kuperwasser,et al. A mouse model of human breast cancer metastasis to human bone. , 2005, Cancer research.
[38] R. Elledge,et al. Premalignant and In Situ Breast Disease: Biology and Clinical Implications , 2005, Annals of Internal Medicine.
[39] A. Sahin,et al. Benign breast diseases: classification, diagnosis, and management. , 2006, The oncologist.
[40] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[41] Greg Finak,et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors , 2006, Breast Cancer Research.
[42] Ferdinando Mannello,et al. Benign breast diseases: classification, diagnosis, and management. , 2006, The oncologist.
[43] Kay Nieselt,et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. , 2006, Cancer research.
[44] M. J. van de Vijver,et al. Classification of ductal carcinoma in situ by gene expression profiling , 2006, Breast Cancer Research.
[45] Martin Widschwendter,et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. , 2006, Cancer research.
[46] K. Mokbel,et al. The role of cyclooxygenase-2 in breast cancer: review , 2008, Breast Cancer Research and Treatment.
[47] R. Vierkant,et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] D. Radisky,et al. Stromal induction of breast cancer: Inflammation and invasion , 2007, Reviews in Endocrine and Metabolic Disorders.
[49] Charles M. Perou,et al. Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.
[50] Jun Yao,et al. Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression , 2008, Clinical Cancer Research.
[51] Jun Yao,et al. Regulation of in situ to invasive breast carcinoma transition. , 2008, Cancer cell.
[52] H. Kuerer,et al. The molecular journey from ductal carcinoma in situ to invasive breast cancer , 2008, Cancer.
[53] Xiao-Jun Ma,et al. Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.
[54] Andrew H. Beck,et al. The fibromatosis signature defines a robust stromal response in breast carcinoma , 2008, Laboratory Investigation.
[55] T. Sørlie,et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.
[56] H. Brentani,et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma , 2008, Breast Cancer Research.
[57] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[58] S. Schnitt. The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin , 2009, Breast Cancer Research.
[59] Andrew H. Beck,et al. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ , 2010, Breast Cancer Research and Treatment.
[60] S. Schnitt,et al. Phenotypic Alterations in Ductal Carcinoma In Situ-associated Myoepithelial Cells: Biologic and Diagnostic Implications , 2009, The American journal of surgical pathology.
[61] Andrew H. Beck,et al. The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma , 2009, Clinical Cancer Research.
[62] R. DePinho,et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice , 2009, Proceedings of the National Academy of Sciences.
[63] A. Howell,et al. Breast tumour stroma is a prognostic indicator and target for therapy , 2009, Breast Cancer Research.
[64] Robert D Cardiff,et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] K. Polyak,et al. Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast , 2009, Proceedings of the National Academy of Sciences.
[66] G. Colditz,et al. Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion , 2010, Cancer.
[67] Jorge S. Reis-Filho,et al. Histological types of breast cancer: How special are they? , 2010, Molecular oncology.
[68] D. Radisky,et al. Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer , 2010, Journal of Mammary Gland Biology and Neoplasia.
[69] J. Reis-Filho,et al. Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.
[70] C. Gialeli,et al. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.
[71] D. Sgroi,et al. The molecular pathology of breast cancer progression , 2011, The Journal of pathology.
[72] Ingebrigt Sylte,et al. Regulation of matrix metalloproteinase activity in health and disease , 2011, The FEBS journal.